§ Glossary
Glossary.
Terms are defined as they are used in this book.
- 3Rs
- Replacement of animal tests by methods without animals, reduction in the number of animals, and refinement of a test so that it causes less pain and distress; ISO 10993-11:2017 asks that all available alternatives be identified.
- 510(k)
- A premarket notification to FDA, needed for a class I or II device that is not exempt; FDA clears the device on substantial equivalence to a legally marketed device.
- 518(a) order
- An order FDA issues under section 518(a) of the Federal Food, Drug, and Cosmetic Act. FDA's order of 10 March 2022 found that the recalled Philips devices present an unreasonable risk of substantial harm to the public health and required the firm to notify health professionals and others.
- accelerated aging
- Storing a packed device at a raised temperature so that the reactions of aging run faster, to estimate an expiry date before real time has passed. It models what heat speeds up, not ozone, cleaning or use.
- accreditation
- For a testing laboratory, recognition by an accreditation body that the laboratory is competent to run the test methods named on its scope, assessed against ISO/IEC 17025. It covers the named methods, not the laboratory as a whole, and it does not judge whether a material or a device is safe.
- activation energy
- The quantity that sets how steeply a reaction speeds up with temperature; for the reactions of polymer aging it typically lies between 0.1 and 0.9 eV.
- acute inflammation
- The first response to the wound of implantation, marked by neutrophils, a kind of white blood cell; it usually resolves in less than a week, and if it persists beyond three weeks it usually indicates an infection.
- acute systemic toxicity
- Adverse effects within 72 hours after a single exposure, or after several within 24 hours, in the definitions of ISO 10993-11:2017.
- additive
- A substance mixed into a polymer to give the plastic a property the chains alone lack, such as flexibility or resistance to oxidation. In nearly all cases it is not chemically bound to the chains, so it can leave the part.
- adsorption
- The holding of molecules on a surface, as distinct from absorption, in which they enter the bulk of a material. Proteins from blood begin to adsorb on a surface within milliseconds of contact.
- aeration
- Holding a device after ethylene oxide sterilization, often heated, so that the gas diffuses out of its materials before release.
- aerodynamic diameter
- The diameter of a sphere with the density of water that settles in air at the same speed as a particle; the size that decides where an inhaled particle deposits, and not the same as the particle's width.
- aging factor (Q10)
- The factor by which a reaction speeds up for each 10 °C rise. The common 10 °C rule takes it as 2, a doubling for each 10 °C.
- allergic contact dermatitis
- The skin reaction of elicitation, at the site of a later contact with a chemical to which the skin has been sensitized.
- analytical evaluation threshold
- AET: the concentration in an extract below which, in ISO 10993-18:2020, the analyst need not identify or quantify an extractable or leachable. It is a dose-based threshold in µg a day converted into µg per mL through the devices extracted, the extract volume, the devices a user meets in a day and any dilution, then divided by the analytical uncertainty factor.
- analytical uncertainty factor
- The factor that lowers the analytical evaluation threshold to cover the spread of response factors between compounds: the average response divided by the response of a compound one standard deviation below the average. FDA's 2024 draft computes it as 1 divided by 1 minus the relative standard deviation of the response factors in a reference database. It has no agreed value: published values run from 1 and 2 to 4 and from 6 to 10, and once the spread is as wide as the average the formula gives no usable value. The factor belongs to the method, not to the device. Not the toxicological uncertainty factor of Chapter 14, which divides a point of departure (Chapters 13 and 17).
- antioxidant
- An additive that delays the oxidation of the chains, including oxidation started by ultraviolet light. Most polyolefins carry 0.05 to 0.10 %, by an additive maker's account.
- antirad
- A stabilizer, typically under 1 % of a material, that acts as an antioxidant against the radicals radiation makes or absorbs its energy.
- ASCA
- FDA's Accreditation Scheme for Conformity Assessment, a voluntary scheme: FDA recognizes accreditation bodies, they assess testing laboratories to ISO/IEC 17025:2017 and the scheme's own specifications, and FDA grants ASCA accreditation. Biocompatibility testing under it is conducted in accordance with 21 CFR 58.
- battery
- A set of tests run together because no single test detects every kind of damage; for genotoxicity under ISO 10993-3:2026, at least two tests without animals, the bacterial reverse mutation test and one test in mammalian cells, as a testing laboratory describes it.
- benchmark dose
- A point of departure computed from every dose group of a study: a curve fitted through the responses gives the dose that would cause a chosen small response, such as a 5 % change, and the calculation starts from the benchmark dose low (BMDL), the "lower one-sided confidence limit" of that dose.
- biocompatibility
- "The ability of a material to perform with an appropriate host response in a specific application", in the definition from a consensus conference of the European Society for Biomaterials (Chester; the proceedings dated 1986 in Williams's 2019 citation). A judgment about a device in a use, not a property of a material; ISO 10993-1:2025 treats biological evaluation as synonymous with biocompatibility evaluation.
- biological evaluation plan
- The plan written at material selection that names, for each contact of a device, the hazards, the exposure, the foreseeable misuse and the acceptance criteria the evaluation will use; the report later documents conformity with it.
- biological evaluation report
- The document that closes the biological evaluation plan, answering each of its questions with evidence; in design control it is verification evidence.
- biological risk estimation
- The step of ISO 10993-1:2025 (clause 6.9) that estimates the biological risk of a device from its hazards and the patient's exposure, so that the evaluation then judges whether the risk is acceptable; FDA does not recognize the clause and sends a US file to ISO 14971:2019 instead.
- blowing agent
- The ingredient of a foam that makes the gas which swells the setting mixture into cells; water in the foams of one 2023 study.
- BPA (bisphenol A)
- A building block of polycarbonate and polysulfone, which devices made of them may hold as a residue; time, high temperature and high pH raise its release.
- carcinogenicity
- The capacity of a substance to cause cancer; with genotoxicity and reproductive and developmental toxicity it is evaluated under ISO 10993-3:2026.
- CE marking
- The mark by which a manufacturer indicates that a device conforms to the EU requirements that apply to it, followed by the notified body's identification number where one took part (Chapter 27).
- Under India's Medical Devices Rules, the authority that licenses the manufacture of class C and D devices and the import of devices of every class.
- chain scission
- The cutting of a polymer chain, by water, oxygen or ozone, or by the free radicals that oxidation and radiation make; each cut makes a new, shorter molecule. Under gamma radiation it happens together with crosslinking (Chapters 5 and 7).
- change control
- The review, approval and documentation of a change to a device's design, materials or production before it is made, including whether the change reopens the biological evaluation; ISO 13485 places design changes in its clause 7.3.9.
- chromatogram
- A detector's signal against time at the outlet of a chromatography column, in which each separated compound appears as a peak whose area grows with its amount.
- chromatography
- Separation of a mixture by partitioning: a moving gas or liquid carries the compounds through a column holding a stationary layer, and each compound travels at its own pace according to how it shares itself between the two.
- CMR substance
- A substance classified as carcinogenic, mutagenic or toxic to reproduction, CMR in the MDR's shorthand. Point 10.4.1 of the MDR's Annex I lists those "of category 1A or 1B", which may exceed 0.1 % by weight only where justified, in a device that is invasive and in direct contact with the body, one that administers substances, gases included, to or from the body, or one that transports or stores them to be administered to the body (Chapter 27).
- coagulation
- The turning of liquid blood into a solid clot. It runs as a cascade, each protein once activated activating the next, and ends in a burst of thrombin, the enzyme that converts fibrinogen into fibrin.
- cohort of concern
- Structures that cause cancer at doses so low that the threshold of toxicological concern excludes them by name: in ICH M7, "aflatoxin-like-, N-nitroso-, and alkyl-azoxy compounds". ISO/TS 21726 does not apply to them.
- complement
- A set of plasma proteins of the immune defense that a foreign surface, such as a dialysis membrane, can set off. Its fragments C3a and C5a recruit white cells, and its terminal complex, sC5b-9, forms in the plasma or on the surface.
- condensate
- The water that collects in a breathing device's gas pathway when warm, moist air cools along the hose and mask. It can carry what the water drew from the plastics, and ISO 18562-4 tests it for leachables.
- consent decree
- A court order whose terms the parties agree to. The consent decree of permanent injunction against Philips Respironics was entered on 9 April 2024; Chapter 26 sets out its terms.
- contact activation
- The route of coagulation that a surface starts with no injury: factor XII binds to the surface through high-molecular-weight kininogen and activates itself, and the chain runs on to thrombin. Negatively charged or nanostructured surfaces bind its enzymes efficiently.
- contact day
- In ISO 10993-1:2025, as testing laboratories reproduce its terms, a day on which a device or one of its components touches tissue, including circulating blood, whatever the length of that contact within the day. Repeated use is counted in contact days.
- contract laboratory
- A testing laboratory that runs chemistry or biological tests on a device maker's behalf.
- correction or removal
- In the Form 483's wording, an action in the field conducted to reduce a risk to health posed by a device. FDA observed that Philips's 2018 field correction for Trilogy ventilators was not reported in writing to FDA.
- Cramer class
- One of three classes of chemical structure, named after Cramer, that set the threshold for a compound without a study. As Munro and colleagues derived them in 1996, and as Builee and colleagues quote them, the lifetime values are 30, 9 and 1.5 µg per kilogram of body weight per day for classes I, II and III; the tested chemicals of class III had the lowest safe doses.
- crosslinking
- The joining of polymer chains to one another, for example by the fragments that oxidation leaves or by a radical that radiation leaves; curing a silicone does it on purpose. Under gamma radiation it happens together with chain scission (Chapters 5 and 7).
- cytotoxic
- Harmful to cells; in device testing, to mammalian cells grown in culture and exposed to a material's extract.
- cytotoxicity
- Harm to cells grown in a dish, read by exposing a layer of cultured cells to a material's extract or to the material itself (ISO 10993-5:2009). A sensitive screen whose failure names no cause.
- De Novo request
- A request to classify a novel device of low to moderate risk; FDA grants it.
- declaration of conformity
- In a premarket submission to FDA, the statement that the device conforms to a recognized edition of a consensus standard: the submitter certifies that the device conforms to all the requirements of that standard, with no deviation from them, as FDA's 2018 guidance on consensus standards defines the declaration. FDA accepts declarations to the 2018 edition of ISO 10993-1 until 1 July 2029 (Chapter 26).
- degradant
- A substance formed when a material breaks down.
- DEHP
- Di-2-ethylhexyl phthalate, a plasticizer of PVC, present at about 30 % to 40 % by weight in PVC softened with it. It is not chemically bound to the PVC, so it passes into stored blood and other fatty liquids.
- denature
- Of a protein: to lose its folded shape, as many proteins do when they adsorb, more on hydrophobic surfaces. Denatured fibrinogen is linked to the activation of platelets.
- design input
- A requirement entered in the design file that the design must meet. A biological evaluation creates its own: material specifications with grade and supplier, cleaning instructions, a useful life and contact limits.
- developmental toxicity
- Harm to the unborn or growing child; named in the title of ISO 10993-3 from its 2026 edition.
- device class
- One of FDA's three categories of regulatory control for devices. FDA ranks them from the lowest risk in class I to the greatest in class III, and class III devices are those for which premarket approval is or will be required (Chapter 26).
- device master file
- A file that a supplier submits to FDA so that the agency can review confidential information, such as a material's formulation, in confidence; the supplier authorizes a client to cite it in an application without giving the client the information.
- diffusion
- The random wandering of molecules through a material, which carries them from where they are crowded to where they are scarce. It brings an unbound additive to a plastic's surface, faster when warm, in a soft polymer and for a small molecule.
- diffusion coefficient
- The one number that sums up how fast a molecule diffuses through a polymer: it rises with temperature, falls as the molecule gets heavier, and is higher in soft polymers than in stiff ones. Upper-bound values plotted by an FDA scientist for device polymers span about nine tenfold steps.
- dose
- The amount of a substance that enters the body each day for each kilogram of body weight, in micrograms per kilogram per day (µg/kg/d) or milligrams per kilogram per day (mg/kg/d). Irritation, an effect at the site of contact, is counted per area of skin instead, in µg/cm².
- dose-based threshold
- The term of FDA's 2024 draft guidance on chemical analysis for the daily intake, in µg a day, that a laboratory's reporting threshold starts from. It is typically a threshold of toxicological concern; for contact of 30 days or more the draft takes 1.5 µg a day as conservatively protective.
- ECMO
- Extracorporeal membrane oxygenation: a machine that oxygenates the patient's blood outside the body. With transfusion in trauma patients, it carries the highest DEHP exposure estimates SCENIHR collected, up to 8,000 to 10,000 µg per kg of body weight per day.
- elicitation
- The second phase of sensitization: a later contact with the same chemical meets the T cells left by induction and raises allergic contact dermatitis, generally at a lower dose than induction needed.
- elution test
- The extract form of the cytotoxicity test: the material is extracted in culture medium with serum, for example for 24 hours at 37 °C, and the extract is placed on the cells, for example for 48 hours.
- endocrine disruption
- Interference with the body's hormones. EU rules treat endocrine-disrupting substances in devices with those that cause cancer, damage genes or harm reproduction (Chapter 27).
- endpoint
- One biological effect that an evaluation must address, such as harm to cells, allergy or damage to genes; ISO 10993-1:2025 calls them biological effects and lists them by contact and duration in four tables.
- environmental stress cracking
- Cracking of a strained polymer in an aggressive environment; for polyurethanes, more common in polyether ones in an oxidizing environment.
- ester link
- The link that joins the units of a polyester. Water cuts it at its carbon double-bonded to oxygen, leaving a hydroxyl end and an acid end, and the acid speeds further cutting.
- ether link
- The link that joins the units of a polyether. Polyether polyurethanes resist hydrolysis but are vulnerable to oxidation.
- ethylene chlorohydrin (ECH)
- The substance ethylene oxide forms when it meets free chloride ions; ISO 10993-7 sets allowable limits for it as for EO. With water, EO forms ethylene glycol, for which the standard sets none.
- ethylene oxide (EO)
- A gas that sterilizes packed devices. Absorbent materials and some plastics take it up and hold it, so the device is aerated afterward.
- evaluator
- The person who writes a device's biological evaluation plan, signs its report and draws the conclusion about the device from its contacts, the chemistry, the toxicology and the tests.
- exaggerated extraction
- In ISO 10993-18:2020, an extraction "intended to result in a greater number or amount of chemical constituents being released" than use. It gives an upper estimate, and ISO 10993-12 notes that it must not change the material chemically.
- exhaustive extraction
- An extraction repeated with fresh solvent of the same kind, for the same fixed time, until a cycle yields less than 10 % of the first, the fraction that FDA's 2024 draft, ISO 10993-18 and ISO 10993-12 all set. FDA's draft measures it as non-volatile residue in each solvent; ISO 10993-12 also allows other means.
- extractable
- A substance released from a device or its material when it is extracted under laboratory conditions and in laboratory liquids (ISO 10993-18:2020): what can come out. Extraction conditions are set harsher than use.
- fibrinogen
- A clotting protein of blood plasma, found in earlier work to be the main protein that plasma deposits on many man-made surfaces; platelets adhere preferentially to surfaces coated with it.
- fibrous capsule
- A layer of dense tissue that encloses an implant and walls it off from the tissue around it, without removing it.
- food simulant
- A liquid that stands in for a food in migration testing, such as the ethanol in which Chapter 6's bottles of new and recycled PET were held.
- foreign-body giant cell
- A large cell formed when several macrophages fuse on a material that no single macrophage can engulf, typically between 10 and 100 µm; giant cells may cause chronic inflammation, with loss of bone around an implant.
- foreign-body reaction
- The response of tissue to an implanted material itself, as distinct from the inflammation of the wound; carried by macrophages and foreign-body giant cells, it can last as long as the implant stays.
- Form FDA 483
- The form on which FDA lists what its investigators observed during an inspection, issued to the firm at the inspection's close. Its observations are not a final FDA determination of whether the firm complies.
- gas chromatography
- Chromatography in a heated column with a stream of gas, which reaches compounds small enough to evaporate: the volatile and semi-volatile ones. Coupled to a mass spectrometer it is GC-MS; headspace GC-MS samples the gas above a sample to catch the most volatile.
- gas pathway
- Every part of a breathing device that the breathed air passes through, from the intake to the mask; anything these parts release into the air can reach the airway.
- genotoxicity
- Damage to DNA. For compounds that damage DNA in the body, a 2006 European medicines guideline assumed by default that no level of exposure is free of risk.
- glass transition
- The temperature below which a polymer turns stiff and glassy; shorter chains lower it, and an accelerated-aging interval should not include it.
- Good Laboratory Practice (GLP)
- The rules that govern how a nonclinical safety study is planned, run, recorded and archived; in the United States, 21 CFR 58. Like accreditation, GLP does not say that a material or a device is safe (Chapter 25).
- granulation tissue
- The new tissue that fills a healing wound; around an implant it may be a precursor to the fibrous capsule.
- guinea pig maximization test
- A sensitization test in guinea pigs, OECD Test Guideline 406: induction by injections, some with an adjuvant, and a patch; a challenge about two weeks later; the skin scored from 0 to 3.
- Haber's rule
- The principle that concentration multiplied by time is a constant. ICH M7 names it as the reason a shorter exposure may take a higher daily intake of a DNA-reactive impurity: the risk is taken to rise with the dose added up over the exposure.
- harm
- "Injury or damage to the health of people, or damage to property or the environment" (ISO 14971:2019, as FDA's human factors guidance reproduces it).
- harmonized standard
- A European standard (EN) whose reference the European Commission has cited in the Official Journal of the EU under a regulation; a device that meets it has a presumption of conformity with the requirements it covers (Chapter 27).
- hazard
- A "potential source of harm" (ISO 14971:2019, as FDA's human factors guidance reproduces it): for a device material, a substance that can leave it, a fragment that can break off or a surface that can provoke a response. It can be named from the material alone.
- hazardous situation
- In ISO 14971:2019, as FDA's training slides reproduce it, one of the "circumstances in which people, property or environment is/are exposed to one or more hazards"; a sequence of events carries a person from the hazard into it. For a substance from a breathing machine's foam, the user's exposure: breathing the machine's air every night for years.
- health hazard evaluation
- A firm's assessment of the risk to health that a problem with its device poses. Philips's 2018 evaluation for its Trilogy ventilators, quoted in FDA's Form 483, counted on a humidifier, a bacterial filter and a healthy lung.
- hemolysis
- The breaking of red cells, which releases their hemoglobin into the plasma. It is counted as a share: the hemoglobin a sample releases into the plasma, divided by all the hemoglobin the diluted blood holds. ISO 10993-4's amended test table separates hemolysis induced by the material from hemolysis induced mechanically by the flow.
- hydrolysis
- The cutting of a chemical link by water. In a polyester polyurethane, water cuts the ester links first, and each cut makes a new molecule.
- hydrophilic
- Water-loving: a surface on which a drop of water spreads flat. Proteins adsorbed on it keep their folded shape better than on a hydrophobic surface.
- hydrophobic
- Water-repelling: a surface on which a drop of water beads up. Proteins adsorb on hydrophobic surfaces in larger amounts and lose their folded shape more than on hydrophilic ones; implantable materials are predominantly hydrophobic.
- identification level
- How far the evidence for a compound's name goes. FDA's 2024 draft names four: confirmed (verified with an authentic reference standard), confident (a single candidate structure), tentative (one or more candidate structures) and unknown (none; a class-only name counts as unknown).
- indirect blood contact
- Contact in which a device touches a fluid that then enters the blood, as a line for saline or a drug does, rather than the blood itself. ISO 10993-4 lists such devices apart from those in direct contact with blood.
- induction
- The first phase of sensitization: the chemical binds to skin proteins, skin and dendritic cells respond, and T cells that recognize it multiply in the lymph node and remain.
- inert
- Doing nothing, in everyday speech, and no material meets that standard: molecules leave every material and proteins arrive on its surface. When a supplier or a paper calls a material inert, this book reads the word as a claim to be checked, that what leaves the material is too little to matter for the use in question.
- intact mucosa
- Unbroken moist lining of a body passage, such as the nose or mouth; one of the four tissue groups of ISO 10993-1:2025.
- integrin
- A receptor protein that spans a cell's outer membrane. Cells hold a surface's adsorbed proteins, not the material, through integrins, for example by binding the RGD site of fibronectin.
- intermittent contact
- Use with at least 24 hours between consecutive tissue contacts, a term added in ISO 10993-1:2025.
- internal standard
- A known amount of one chosen compound added to an extract, against whose signal the compounds without a standard of their own are counted.
- irritation
- Local damage that a substance does where it touches, whose size follows the dose at each contact; no record of an earlier contact carries over. Devices are tested for it under ISO 10993-23.
- IS 17932
- A series of Indian standards that adopts parts of ISO 10993 as modified or technically equivalent rather than identical; its Part 1:2023 is ISO 10993-1:2018 modified.
- ISO 18562
- The series of standards for the biological evaluation of a breathing device's gas pathway: the evaluation within risk management, and tests of the delivered air for particles and volatile organic compounds and of condensate for leachables.
- kilogray (kGy)
- The unit of radiation dose: the energy absorbed by each kilogram of material. A contract sterilizer gives 25 to 40 kGy as an example of a sterilizing dose.
- leachable
- A substance released from a device during its clinical use (ISO 10993-18:2020): what does come out where the patient is. Leachables are generally a subset of extractables; a substance that forms only during use is the exception.
- leukopenia
- A fall in the white-cell count of the blood. With strongly complement-activating dialysis membranes it appears early in a treatment and is transient.
- limited, prolonged and long-term contact
- The three duration bands of ISO 10993-1, which its 2025 edition keeps: limited contact, up to 24 hours; prolonged contact, from 24 hours to 30 days; and long-term contact, more than 30 days. ISO 18562-1:2017 has bands of its own, limited, prolonged and permanent; in the accounts of a test laboratory and an instrument maker its permanent band is 30 days or more, so it starts on day 30, a day before long-term contact (Chapters 2 and 19).
- lipophilic
- Fat-loving: dissolving better in fats than in water. Plasticizers leach more into lipophilic solutions, such as blood with its plasma lipids, than into saline.
- liquid chromatography
- Chromatography with a liquid as the moving phase, which reaches larger, non-volatile compounds and some semi-volatile ones. Coupled to a mass spectrometer it is LC-MS, most often through electrospray, run in positive and negative mode.
- LOAEL
- Lowest-observed-adverse-effect level: the smallest dose in a toxicity study at which the study saw an adverse effect. A study with no dose free of effect, such as the 1953 guinea pig study behind EPA's reference dose for DEHP, has a LOAEL and no NOAEL.
- local lymph node assay
- A sensitization test in mice, EU test method B.42, that reads induction alone: a substance counts as a sensitizer when lymphocytes in the draining lymph nodes multiply to at least three times the level in mice given only the vehicle.
- macrophage
- A white blood cell that clears debris by phagocytosis; macrophages are the dominant cells around an implanted material, and they fuse into giant cells on materials too large to engulf.
- Magnusson and Kligman scale
- The scale on which the guinea pig maximization test scores each challenge site, about 48 and 72 hours after the challenge begins: 0, no visible change; 1, discrete or patchy redness; 2, moderate and confluent redness; 3, intense redness and swelling (OECD Test Guideline 406).
- margin of safety
- The tolerable intake, or the tolerable contact level, divided by the worst-case estimated exposure dose: how many times the estimated dose fits inside the tolerable one. A value above 1 indicates a low toxicological risk, in one consultancy's reading of ISO 10993-17:2023, and FDA's 2026 town-hall slides pair that outcome with a value below 1 held with root cause analysis and adequate risk management.
- mass spectrometer
- An instrument that gives molecules an electric charge, sorts the charged pieces by mass and counts how many arrive at each mass.
- mass spectrum
- The pattern of masses a mass spectrometer records for one compound, which follows from its structure and is matched against a library of spectra to name it.
- masterbatch
- A concentrate of additive, at 5 to 30 % or more, that is diluted into the plain polymer when a part is made.
- MDR
- The EU's Medical Device Regulation, Regulation (EU) 2017/745 of 5 April 2017. Its Annex I sets out what a device must meet for safety and performance, section 10 covering chemical, physical and biological properties (Chapter 27).
- medical devices testing laboratory
- Under India's Medical Devices Rules, a laboratory registered to test devices on a maker's behalf; CDSCO registers such laboratories on Form MD-40.
- medical grade
- A supplier's word for a resin made and documented for devices: a recipe with documents attached, not a clearance or approval by FDA, which does not clear or approve individual materials.
- modifying factor
- The product of a compound's uncertainty factors, in ISO 10993-17:2023's definition the "mathematical product of uncertainty factors". The point of departure divided by it gives the tolerable intake.
- monomer
- The small molecule a polymer chain is built from. Some of it is left over after manufacture, as BPA can be in polycarbonate and vinyl chloride in PVC, and it can leave the part.
- mutagenic
- Able to cause mutations, changes in DNA, as judged in laboratory tests on a material or its extract.
- Mutual Acceptance of Data
- The OECD's scheme for GLP, whose purpose is that GLP data from a certified test facility are accepted in the OECD's member countries; India became a full adherent on 3 March 2011.
- negative control
- In a test run, a material expected to give almost no effect, run beside the test article to show the run is sound. In the hemolysis test under ASTM F756-17, a run is valid only if the negative control releases less than 2 % of the blood's hemoglobin.
- New Foam
- The consent decree's name for the sound-damping foam that replaces the recalled polyester polyurethane foam; FDA's summary calls it silicone-based. The decree has an independent expert review its testing (Chapter 26).
- NOAEL
- No-observed-adverse-effect level: the largest dose in a toxicity study at which the study saw no adverse effect. It can only be a dose the study tested.
- non-intentionally added substance (NIAS)
- Any substance in a material that nobody put there on purpose: a fragment of the polymer, a by-product of a reaction or a transformation product. The ring-shaped oligomers that can form in a PET melt are one kind.
- non-volatile residue
- What remains when an extract is dried and weighed. Its weight from cycle to cycle shows when an exhaustive extraction may stop, and it estimates the non-volatile and some semi-volatile extractables against which the identified total is checked.
- notified body
- A conformity assessment body designated under the EU's device regulations; where a device's assessment involves one, it reviews the manufacturer's technical documentation (Chapter 27).
- oligomer
- A short chain of only a few units, present in every batch of a polymer. Small enough to move through a plastic as an additive does.
- parenteral
- Of a study or a route: the compound given by injection or infusion. FDA does not recognize the two clauses of ISO 18562-1:2024 that let parenteral data stand in, without modification, for missing inhalation data.
- partition ratio
- The concentration in the plastic divided by the concentration in the liquid once both have stopped changing. A 2010 European Commission report uses defaults of 1 for a substance that dissolves readily in the liquid and 1,000 for a fat-loving substance in a watery liquid.
- partitioning
- The sharing of a substance between a plastic and the liquid touching it, until as many molecules cross back as cross out; a molecule ends up mostly where it dissolves better.
- patch test
- A clinical test in which suspected allergens are held against the skin and the skin is read days later for a reaction.
- PE-PUR foam
- Polyester-based polyurethane foam, the sound-damping foam of the Philips Respironics machines recalled in June 2021, which can break down in heat and humidity into pieces and chemicals a patient could breathe or swallow.
- phagocytosis
- The taking in of a particle by a cell, which wraps its membrane around the particle and draws it inside; macrophages take in particles under 10 µm this way.
- plasticizer
- An additive that makes a plastic flexible, typically 10 to 70 % of the weight; PVC takes about 80 % of all plasticizers used.
- platelets
- The cell fragments in blood that start a clot (Chapter 8). On a device they bind the fibrinogen adsorbed to the surface through a receptor, release their stores and draw white cells to them.
- PM10
- The mass of particles with a diameter of 10 µm or less in a cubic meter of gas. ISO 18562-2 limits it at 150 µg/m³ in the delivered gas, in three companies' accounts of the standard.
- PM2.5
- The mass of particles with a diameter of 2.5 µm or less in a cubic meter of gas. ISO 18562-2 limits it at 12 µg/m³ in the delivered gas, in three companies' accounts of the standard.
- point of departure
- The dose a risk calculation starts from, defined in ISO 10993-17:2023 as a "low point on a toxicological dose-response curve established from experimental or observational data". It can be a NOAEL, a LOAEL or a benchmark dose, and the standard says the most critical clinically relevant value is selected.
- polarity
- The uneven spread of electric charge across a molecule, which decides what a liquid dissolves. Water is polar, hexane non-polar, and an alcohol such as isopropanol or ethanol semi-polar, so an extraction uses solvents of different polarity to draw out different kinds of molecule.
- polymer
- A long chain built by joining small molecules, the monomers, end to end many times over; a plastic part is a mass of such chains, the frame that holds everything else.
- polyolefin
- The family of polyethylene and polypropylene, which carry antioxidants and may hold residual catalyst.
- positive control
- In a test run, a material expected to give a clear effect, run beside the test article to show the test can detect one. In the hemolysis test under ASTM F756-17, a run is valid only if the positive control releases more than 5 % of the blood's hemoglobin.
- post-cure
- A further bake of a cured silicone part that removes by-products of the cure and reduces short chains.
- premarket approval application (PMA)
- The submission a class III device needs; FDA approves it.
- presumption of conformity
- The standing a device gains by meeting a harmonized standard: it is taken to meet the requirements of the regulation that the standard covers. Following the standard is voluntary (Chapter 27).
- protein coat
- The proteins adsorbed on a surface wetted by blood or tissue fluid, taken together. It forms within milliseconds to minutes of contact and goes on changing; cells meet the coat, not the material.
- Q10
- The factor by which a rate of aging rises for each 10 °C. The convention Q10 = 2, a doubling per 10 °C, is older than the 1998 trade-journal protocol that gives it as the usual value for medical polymers, with an oven no hotter than 60 °C and real-time confirmation.
- QMSR
- The Quality Management System Regulation, FDA's amended rule for device makers' quality systems, effective 2 February 2026. It incorporates ISO 13485:2016 by reference and, for class II and class III devices and some class I devices, takes its design and development requirements from the standard's clause 7.3; it does not incorporate ISO 14971. Design controls were required before it, under the Quality System Regulation.
- REACH
- The EU's chemicals law. It lists substances of very high concern, DEHP among them, and the MDR uses its identification of endocrine disruptors (Chapters 11 and 27).
- reactive additive
- An additive that joins the polymer chain as the chain forms, the exception to the rule that additives are not bound.
- real-time aging
- Storage at the labeled conditions for the full shelf life, which confirms a date set by accelerated aging.
- recognized consensus standard
- A consensus standard that FDA recognizes by entering one edition of it, in full or in part, in its database of recognized standards; the record for each edition gives the date of entry, and a premarket submission can then make a declaration of conformity to that edition. FDA also publishes each change to the database in the Federal Register, as a list of modifications (Chapter 26).
- reconstructed human epidermis
- A tissue model of the skin's outer layer built from human cells: layers of human skin cells grown into a tissue, on which irritation is tested in the laboratory without animals. ISO 10993-23 has included it among its test procedures since its first edition in 2021, and the standard's Amendment 1 of 2025 adds further models (Chapters 11 and 18).
- relative response factor
- The ratio of a compound's signal to the internal standard's signal for equal amounts. Counting by the internal standard assumes it is 1; in a 2025 FDA study of 106 polymer additives it ran from 0.014 to 2.551 in GC-MS and over wider ranges in LC-MS.
- relative standard deviation
- The standard deviation of a set of values expressed as a fraction of their average; for response factors, the measure of how widely compounds' responses spread.
- residual
- The sterilant, or a product of it, left in a material when a sterilization process ends; for ethylene oxide, the residual EO itself and the ethylene chlorohydrin it forms. Distinct from a residue, which processing leaves.
- residual risk
- The risk that remains once risk controls are in place (ISO 14971:2019, as FDA's human factors guidance reports it); a benefit–risk analysis justifies why the device's benefits outweigh it.
- residue
- Whatever the making of a part leaves in or on it without meaning to: leftover monomer and catalyst from making the resin (Chapter 3), and the mold release agents, joining solvents, adhesives and cleaning fluids of processing. Unless it has reacted into the chains, it can diffuse out like any unbound additive.
- respirable fraction
- The part of inhaled particles that reaches the gas-exchange region of the lungs; under the conventions adopted from CEN, half of particles with an aerodynamic diameter of 4 µm.
- retention time
- The time a compound takes to emerge from a chromatography column, which depends on the compound, the column and the conditions.
- RGD
- A run of three amino acids, arginine, glycine and aspartic acid, named after their one-letter codes; carried by fibronectin and vitronectin, it is a site that cells' integrins bind.
- risk
- The "combination of the probability of occurrence of harm and the severity of that harm" (ISO 14971:2019, as a 2025 Health Canada guidance reproduces it). For a device material it depends on the route and the dose, which only the use sets.
- Rule 7
- The rule of India's Medical Devices Rules, 2017, that orders the standards a device must conform to: Indian standards first, then ISO, IEC or pharmacopoeia standards where no Indian standard exists, then the validated manufacturer's standards where neither exists.
- running device
- The generic home breathing machine designed through this book, modeled on no single maker's design: intake and filter, blower with a sound-damping foam, sensors, controller and display, heated humidifier with a water chamber, hose, and nasal mask with a silicone cushion and fabric headgear.
- sensitization
- The process by which a first contact teaches the immune system to recognize a chemical, so that a later contact raises an allergy. It runs in two phases, induction and elicitation.
- shear
- The dragging of one layer of a melt past the next as a turning screw pushes it along. It stretches chains that heat has already set moving, and some of them break; more shear breaks more chains.
- shear stress
- The drag that faster layers of a flowing liquid exert on slower layers and on the wall. In blood, high shear brings von Willebrand factor into platelet activation, and extremely high shear breaks red cells.
- silicone elastomer
- A rubber made of chains of silicon and oxygen carrying methyl groups, reinforced with silica and cured, its chains joined into a network, with a platinum catalyst, an organic peroxide or a tin compound.
- simulated-use extraction
- In ISO 10993-18:2020, an extraction "using a method that simulates clinical use". It estimates what use itself releases, but it is still made in a laboratory, so what it yields are extractables, which stand for leachables only as far as the resemblance to use has been shown.
- Under India's Medical Devices Rules, the authority that licenses the manufacture of class A and B devices.
- stimulation index
- In the local lymph node assay, the multiplication of lymphocytes in the draining lymph nodes of treated mice divided by that in mice given the vehicle alone; EU test method B.42, written for chemicals, counts a substance as a sensitizer at 3 or more.
- structural alert
- A part of a molecule that marks a possible reaction with DNA. A compound with an alert is held to the threshold for substances that may damage DNA, not to the value of its Cramer class.
- systemic toxicity
- Harm at a site distant from the contact, which needs the substance absorbed and distributed. ISO 10993-11 sorts its studies by duration: acute, subacute, subchronic and chronic.
- TD50
- The dose that gives a tumor incidence of 50 % in the most sensitive species and at the most sensitive site. ICH M7 divides it by 50,000, along a straight line from zero, to reach the dose at an excess lifetime cancer risk of 1 in 100,000.
- technical documentation
- The manufacturer's file that shows how an EU device meets the requirements of the MDR's Annex I, the biological evaluation included (Chapter 27).
- test article
- The sample tested in place of the device. FDA compares it with the device in its final finished form, in formulation, processing, sterilization and geometry.
- thermoplastic elastomer
- A soft, rubber-like plastic that melts for molding; the material chosen in this book for the running device's hose and cuff.
- thoracic fraction
- The part of inhaled particles that passes into the chest; under the conventions adopted from CEN, half of particles with an aerodynamic diameter of 10 µm.
- threshold of toxicological concern
- TTC: an intake low enough that harm is very unlikely even for a compound no one has tested, in ISO/TS 21726:2019 a "level of exposure for constituents, below which there would be no appreciable risk to human health". It is read from tested chemicals: the fifth percentile of their no-adverse-effect doses, divided by 100.
- tolerable air concentration
- The most of one compound that each cubic meter of breathed air may carry: the tolerable intake multiplied by the patient's body mass, divided by the volume of air breathed in a day.
- tolerable contact level
- For an irritant, the limit that an amount per area of contact is compared with: in ISO 10993-17:2023, an "estimate of the surface-contact exposure to an identified constituent ... that is without appreciable irritation", in µg/cm².
- tolerable exposure
- A second limit of the 2002 edition of ISO 10993-17, set for the patient and the use; the 2023 edition dropped it and handles the patient and the use in the estimate of exposure instead.
- tolerable intake
- In ISO 10993-17:2023, an "estimate of the daily exposure of an identified constituent ... that is considered to be without appreciable harm to health", obtained by dividing the point of departure by the modifying factor. It is counted per kilogram, so a light patient and a heavy one share one value.
- topography
- A surface's shape at the scale of cells. With chemistry and wettability, it changes the proteins a surface adsorbs and the response of cells.
- total exposure period
- In ISO 10993-1:2025, as a laboratory reproduces the term, the number of contact days between the first and the last use of a device. ISO 18562's 2024 edition uses the same term.
- toxicological screening limit
- TSL: in ISO 10993-17:2023, a "cumulative exposure dose" of an identified constituent "over a specified time period", read by a consultancy as the daily threshold multiplied by days: 120 µg for contact of 30 days or less and 600 µg beyond. A constituent whose dose stays below it needs no further systemic risk assessment, in the reading of Gruber of the Johner Institute, another consultancy.
- traceability
- The links in an evaluation file from each contact to its category and duration, the biological effects listed for it, the data that address each effect and the conclusion drawn, so that someone other than the author can follow each conclusion back.
- tracheostomy
- An opening into the windpipe through the neck that bypasses the nose.
- transformation product
- A new molecule made from an additive during processing, such as the phosphate that an antioxidant phosphite becomes in the melt. A resin's recipe does not list it.
- Tripartite guidance
- The Tripartite Biocompatibility Guidance for Medical Devices, issued in 1986 by FDA and two foreign agencies (the United Kingdom and Canada, in a 1997 review), a guidance on the selection of toxicological tests for device safety; followed in the United States by FDA's memoranda G87-1 (1987) and G95-1 (1995).
- UHMWPE
- Ultra-high molecular weight polyethylene, the bearing material of knee implants, in which radiation-made radicals have been found after several years on the shelf.
- uncertainty factor
- A number by which a point of departure is divided, each one for a way in which the study differs from the patient: animal to human and person to person (10 each by default), a study shorter than the exposure, a different route, and data of reduced reliability.
- urethane link
- The link an isocyanate forms with a polyol, tying a polyurethane's segments into its chain; it hydrolyzes about ten times more slowly than an ester link.
- USP Class VI
- A certificate that a material passed three animal tests that chapter 88 of the United States Pharmacopeia set out, as trade and supplier articles describe them: extracts injected into mice and into rabbit skin, and rods implanted in rabbit muscle, over three to seven days. It describes the resin as tested, not the finished device.
- validation
- In design control, the check that the finished device meets the needs of its users, as distinct from verification against the design's requirements.
- verification
- In design control, the evidence that a design meets the requirements set for it. The biological evaluation report is verification evidence for the device's biological requirements.
- viability
- The share of living cells after exposure, against untreated cells. In the cytotoxicity test, a fall of more than 30 %, to below 70 %, marks a material as cytotoxic, as laboratories and a 2023 paper state the criterion.
- volatile organic compound (VOC)
- A carbon compound small enough to evaporate at the temperature of use, so that air can take it from a plastic. ISO 18562-3 measures VOCs in the gas a breathing device delivers.
- Vroman effect
- The exchange in which other proteins displace the abundant proteins that adsorbed on a surface first, so the protein coat changes after it forms. It does not run on every surface: on glass-like surfaces, which set off clotting, fibrinogen was replaced mainly by high-molecular-weight kininogen and less by factor XII, while on water-repelling surfaces that do not set off clotting it was not exchanged.
- wettability
- How readily water spreads on a surface, seen in the angle at the edge of a drop; it shapes how much protein a surface adsorbs and how far that protein unfolds.
- worst case
- The choice of sample and conditions expected to release the most. In FDA's 2024 draft guidance the sample is the finished device, whole, typically the model with the largest surface area and the most sterilization or reprocessing cycles.
- worst-case estimated exposure dose
- The dose a patient is estimated to receive from a device, in ISO 10993-17:2023 an "exposure dose that is a maximum value for a specified intended clinical-use scenario". It is built from the quantity in the device, a scaling factor, the patient's body mass and the days over which the release is spread, or from the highest quantity a release study measures in one day.
Let's Talk